WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...
August 2024
Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China
Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...
China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages
The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply...
China Commits to Optimizing Market Access for Emerging Sectors and Global Scientific Collaboration
The General Office of the Communist Party of China (CPC) Central Committee and the State...
Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...
BrightGene Bio Receives FDA Clearance for Generic Eribulin APIs, Advancing in Breast Cancer Treatment
BrightGene Bio-Medical Technology Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...
Daiichi Sankyo Launches Tarlige for Diabetes Peripheral Neuropathic Pain in China
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch...
Changchun GeneScience Pharmaceutical Expands Reach with HuChuang Union Partnership
Changchun GeneScience Pharmaceutical Co., Ltd, a Chinese pharmaceutical enterprise, has established a partnership with HuChuang...
SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research
SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within...
Jiangsu Hengrui Pharmaceuticals Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China with shares traded...
Akeso Biopharma’s Ivonescimab Earns Category 1 Recommendation in China’s 2024 Lung Cancer Clinical Guideline
Akeso Biopharma, a China-based pharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 9926),...
Hangzhou Biosunpharma’s OB756 New Drug Application Accepted for Myelofibrosis Treatment by China’s NMPA
Hangzhou Biosunpharma Co., Ltd. has announced that the National Medical Products Administration (NMPA) has accepted...
R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first...
US Congressmen Call for FDA Investigation into Clinical Trials at China’s Military Hospitals
US lawmakers are intensifying their scrutiny of the involvement of Chinese military hospitals in hosting...
Jiangsu Hansoh and GSK Receive FDA Breakthrough Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a prominent Chinese pharmaceutical company, and its UK...
Henlius Biotech Secures Exclusive Rights to Commercialize Convalife’s Generic Neratinib in China and Abroad
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally
Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful...
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...